Oriola-KD makes changes to management team

Henry Fogels adds acting director general of wholesale business in Russia to his duties

Henry Fogels, general director of Oriola-KD's Pharmaceutical Retail business in Russia (OOO Vitim) has been nominated, in addition to his current duties, to the position of acting general director of Oriola-KD's Pharmaceutical Wholesale business in Russia.

Fogels will continue as a member of Oriola-KD's Group Management Team, being responsible for Oriola-KD's businesses in Russia.

Fogels has replaced Vladimir Knyazev, who left the Espoo, Finland-based company this month.

You may also like

Manufacturing

Oriola-KD to sell healthcare trade business to Mediq

Dutch firm to acquire Oriola-KD businesses across Scandinavia and Europe
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Regulatory

Trump warning: drugmakers must expand US manufacturing or face tariffs

The president announced a new 100% tariff on branded medicines unless manufacturers are already building US plants
Manufacturing

Automate Reactex glass reactor systems easily with Hitec Zang

Labtex, backed by more than 20 years of expertise in specialist laboratory and process chemistry equipment, is bringing advanced automation to its REACTEX glass reactor systems through innovative solutions from Hitec Zang
Training & Education

Celebrating 50 years of the Qualified Person (QP) and 35 Years of NSF Training

From York, where it all began, to today’s global stage—discover the story of the Qualified Person and the vital role they play in protecting patients
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Subscribe now